US 5641504A
· Lee
· 1997
[cited by examiner]
US 7838025B2
· Koenig et al.
· 2010
[cited by applicant]
US 8133917B2
· Rimando et al.
· 2012
[cited by applicant]
US 8252845B1
· Rimando et al.
· 2012
[cited by applicant]
US 9980924B2
· Meyskens et al.
· 2018
[cited by applicant]
US 20040115331A1
· Eggink et al.
· 2004
[cited by applicant]
US 20040146482A1
· Pauly
· 2004
[cited by examiner]
US 20050158258A1
· Fisher
· 2005
[cited by examiner]
US 20060057231A1
· Rimando et al.
· 2006
[cited by applicant]
US 20070020220A1
· Osborne
· 2007
[cited by applicant]
CN 1905891A
· 2007
[cited by applicant]
CN 101268145A
· 2008
[cited by applicant]
CN 108883036A
· 2018
[cited by applicant]
CN 110731929A
· 2020
[cited by applicant]
WO 2000016752A2
· 2000
[cited by applicant]
WO 2004037225A2
· 2004
[cited by applicant]
WO 2016036999A1
· 2016
[cited by applicant]
WO 2019060357A1
· 2019
[cited by applicant]
Moy et al., “Sandalwood Album Oil as a Botanical Therapeutic in Dermatology,” J. Clin. Aesthet. Dermatol. 10(10):34-39 (2017).
[cited by applicant]
Moya-Camarena et al., “Conjugated Linoleic Acid is a Potent Naturally Occurring Ligand and Activator of PPARalpha,” J. Lipid Res. 40(8):1426-1433 (1999).
[cited by applicant]
Nugteren et al., “Naturally Occurring Conjugated Octadecatrienoic Acids are Strong Inhibitors of Prostaglandin Biosynthesis,” Prostaglandins 33(3):403-417 (1987).
[cited by applicant]
Oh et al., “The Molecular Revolution in Cutaneous Biology: EDC and Locus Control,” J. Invest. Dermatol. 137(5):e101-e104 (2017).
[cited by applicant]
Ohtera et al., “Identification of a New Type of Covalent PPARγ Agonist Using a Ligand-Linking Strategy,” ACS Chem. Biol. 10(12):2794-2804 (2015).
[cited by applicant]
Li et al., “The Role of Ceramides in Skin Homeostasis and Inflammatory Skin Diseases,” J. Dermatol. Sci. 97(1):2-8 (2020).
[cited by applicant]
Rageeb et al., “In Vitro Anti-Inflammatory Activity of Pterocarpus Marsupium Roxb. Stem Bark on Albino Rats,” Journal of Pharmaceutical and Scientific Innovation 1(2):21-25 (2012).
[cited by applicant]
Rimando et al., “Pterostilbene, a New Agonist for the Peroxisome Proliferator-Activated Receptor Alpha-Isoform, Lowers Plasma Lipoproteins and Cholesterol in Hypercholesterolemic Hamsters,” J. Agric .Food Chem. 53(9):34…
[cited by applicant]
Rivier et al., “Differential Expression of Peroxisome Proliferator-Activated Receptor Subtypes During the Differentiation of Human Keratinocytes,” J. Invest. Dermatol. 111(6):1116-1121 (1998).
[cited by applicant]
Rivier et al., “Peroxisome Proliferator-Activated Receptor-Alpha Enhances Lipid Metabolism in a Skin Equivalent Model,” J. Invest. Dermatol. 114(4):681-687 (2000).
[cited by applicant]
Robertshaw et al., “Pioglitazone: A Promising Therapy for Psoriasis,” Br. J. Dermatol. 152(1):189-191 (2005).
[cited by applicant]
Roupe et al., “Pharmacometrics of Stilbenes: Seguing Towards the Clinic,” Curr. Clin. Pharmacol. 1(1):81-101 (2006).
[cited by applicant]
Schleehauf, Sabinsa Cosmetics' pTeroWhite, Feb. 13, 2019, <https://www.cosmeticsandtoiletries.com/formulating/category/natural/Sabinsa-Cosmetics-pTeroWhite-505801751.html>.
[cited by applicant]
Schmuth et al., “Role of PPAR, LXR, and PXR in Epidermal Homeostasis and Inflammation,” Biochim. Biophys. Acta. 1841(3):463-473 (2014).
[cited by applicant]
Schütz et al., “Bio-Derived Hydroxystearic Acid Ameliorates Skin Age Spots and Conspicuous Pores,” Int. J. Cosmet. Sci. 41(3):240-256 (2019).
[cited by applicant]
Sertznig et al., “Peroxisome Proliferator-Activated Receptors (PPARs) in Dermatology: Challenge and Promise,” Dermatoendocrinol. 3(3):130-135 (2011).
[cited by applicant]
Shafiq et al., “Pilot Trial: Pioglitazone Versus Placebo in Patients with Plaque Psoriasis (the P6),” Int. J. Dermatol. vol. 44(4):328-333 (2005).
[cited by applicant]
Shang et al., “Cooperative Cobinding of Synthetic and Natural Ligands to the Nuclear Receptor PPARγ,” eLife 7:e43320 (2018).
[cited by applicant]
Sierra et al., “Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARalpha Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents,” J. Med. Chem. 50(4):685-695 (2007).
[cited by applicant]
Takeda et al., “Strawberry Seed Extract and its Major Component, Tiliroside, Promote Ceramide Synthesis in the Stratum Corneum of Human Epidermal Equivalents,” PLoS One 13(10):e020561 (2018).
[cited by applicant]
Wiechers et al., “A New Mechanism of Action for Skin Whitening Agents: Binding to the Peroxisome Proliferator- Activated Receptor,” Int. J. Cosmet. Sci. 27(2):123-132 (2005).
[cited by applicant]
Ximenynic Acid, Jun. 18, 2019, entire document, https://en.wikipedia.org/w/index.php?title=Ximenynic_acid&oldid=902336690.
[cited by applicant]
Yamamoto et al., “Molecular Association Model of PPARα and its New Specific and Efficient Ligand, Pemafibrate: Structural Basis for SPPARMα,” Biochem. Biophys. Res. Commun. 499(2):239-245 (2018).
[cited by applicant]
Zhang et al., “Topically Applied Ceramide Accumulates in Skin Glyphs,” Clin. Cosmet. Investig. Dermatol. 8:329-337 (2015).
[cited by applicant]
Zoete et al., “Peroxisome Proliferator-Activated Receptor Structures: Ligand Specificity, Molecular Switch and Interactions with Regulators,” Biochim. Biophys. Acta. 1771(8):915-925 (2007).
[cited by applicant]
Majewski et al., “Accelerated Barrier Repair in Human Skin Explants Induced with a Plant-Derived PPAR-a Activating Complex via Cooperative Interactions”, PMID: 34566418 PMCID: PMC8458040 DOI: 10.2147/CCID.S325967, Clin …
[cited by applicant]
Al Yacoub et al., “PPARdelta is a Type 1 IFN Target Gene and Inhibits Apoptosis in T Cells,” J. Invest. Dermatol. 128(8):1940-1949 (2008).
[cited by applicant]
Angeli et al., “Peroxisome Proliferator-Activated Receptor Gamma Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response,” J. Immunol. 170(10):5295-5301 (2003).
[cited by applicant]
Bais et al., “The Molecular Regulation of Stilbene Phytoalexin Biosynthesis in Vitis Vinifera During Grape Berry Development,” Aust. J. Plant Physiol. 27:425-433 (2000).
[cited by applicant]
Batheja et al., “Effects of Growth Conditions on the Barrier Properties of a Human Skin Equivalent,” Pharm Res. 26(7):1689-1700 (2009).
[cited by applicant]
Behshad et al., “A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis,” Arch. Dermatol. 144(1):84-88 (2008).
[cited by applicant]
Berger et al., “The Mechanisms of Action of PPARs,” Annu. Rev. Med. 53:409-435 (2002).
[cited by applicant]
Billoni et al., “Expression of Peroxisome Proliferator Activated Receptors (PPARs) in Human Hair Follicles and PPAR alpha Involvement in Hair Growth,” Acta Derm. Venereol. 80(5):329-334 (2000).
[cited by applicant]
Boguniewicz et al., “Atopic Dermatitis: A Disease of Altered Skin Barrier and Immune Dysregulation,” Immunol. Rev. 242(1):233-246 (2011).
[cited by applicant]
Bongartz et al., “Treatment of Active Psoriatic Arthritis with the PPARgamma Ligand Pioglitazone: An Open-Label Pilot Study,” Rheumatology 44(1):126-129 (2005).
[cited by applicant]
Braissant et al., “Differential Expression of Peroxisome Proliferator-Activated Receptor-alpha, -beta, and -gamma During Rat Embryonic Development,” Endocrinology 139(6): 2748-2754 (1998).
[cited by applicant]
Braissant et al., “Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution pf PPAR-alpha, -beta, and -gamma in the Adult Rat,” Endocrinology 137(1):354-366 (1996).
[cited by applicant]
Chawla et al., “Nuclear Receptors and Lipid Physiology: Opening the X-Files,” Science 294(5548):1866-1870 (2001).
[cited by applicant]
Chon et al., “Keratinocyte Differentiation and Upregulation of Ceramide Synthesis Induced by an Oat Lipid Extract via the Activation of PPAR Pathways,” Exp. Dermatol. 24(4):290-295 (2015).
[cited by applicant]
Cox, “Rationally Designed PPARδ-Specific Agonists and Their Therapeutic Potential for Metabolic Syndrome,” Proc. Natl. Acad. Sci. USA 114(13):3284-3285 (2017).
[cited by applicant]
Dahten et al., “Systemic PPARgamma Ligation Inhibits Allergic Immune Response in the Skin,” J. Invest. Dermatol. 128(9):2211-2218 (2008).
[cited by applicant]
Del Rosso et al., “Understanding the Epidermal Barrier in Healthy and Compromised Skin: Clinically Relevant Information for the Dermatology Practitioner,” J. Clin. Aesthet. Dermatol. 9(4 suppl 1):S2-S8 (2016).
[cited by applicant]
Demento et al. “Improving the Quality of Skin Barrier Function with PPAR-Activating Technology,” Journal of the American Academy of Dermatology 70:AB64 (2014).
[cited by applicant]
Downie et al., “Peroxisome Proliferator-Activated Receptor and Farnesoid X Receptor Ligands Differentially Regulate Sebaceous Differentiation in Human Sebaceous Gland Organ Cultures in vitro,” British J. Dermatol. 151(4…
[cited by applicant]
Dubrac et al., “Peroxisome Proliferator-Activated Receptor-alpha Activation Inhibits Langerhans Cell Function,” J. Immunol. 178(7):4362-4372 (2007).
[cited by applicant]
Dubrac et al., “PPAR-alpha in Cutaneous Inflammation,” Dermatoendocrinol. 3(1):23-26 (2011).
[cited by applicant]
Dwivedi et al., “Chemopreventive Effects of Sandalwood Oil on Skin Papillomas in Mice,” Eur. J. Cancer Prev. 6(4):399-401 (1997).
[cited by applicant]
Eastham et al., “PPARalpha/gamma Expression and Activity in Mouse and Human Melanocytes and Melanoma Cells,” Pharm. Res. 25(6):1327-1333 (2008).
[cited by applicant]
Eissa et al., “Human Tissue Kallikreins as Promiscuous Modulators of Homeostatic Skin Barrier Functions,” Biol. Chem. 389(6):669-680 (2008).
[cited by applicant]
Elias et al., “Interactions Among Startum Corneum Defensive Functions,” Exp. Dermatol. 14(10):719-726 (2005).
[cited by applicant]
Evans et al., “PPARs and the Complex Journey to Obesity,” Nat. Med. 10(4):355-361 (2004).
[cited by applicant]
Faveeuw et al., “Peroxisome Proliferator-Activated Receptor gamma Activators Inhibit Interleukin-12 Production in Murine Dendritic Cells,” FEBS Lett. 486(3):261-266 (2000).
[cited by applicant]
Fluhr et al., “Topical Peroxisome Proliferator Activated Receptor Activators Accelerate Postnatal Stratum Corneum Acidification,” J. Invest. Dermatol. 129(2):365-374 (2009).
[cited by applicant]
Forman et al., “15-Deoxy-delta 12, 14-prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPAR Gamma,” Cell 83(5):803-812 (1995).
[cited by applicant]
Forman et al., “Hypolipidemic Drugs, Polyunsaturated Fatty Acids, and Eicosanoids are Ligands for Peroxisome Proliferator-Activated Receptors Alpha and Delta,” Proc. Natl. Acad. Sci. U S A 94(9):4312-4317 (1997).
[cited by applicant]
Goleva et al., “Epithelial Barrier Repair and Prevention of Allergy,” J. Clin. Investl. 129(4):1463-1474 (2019).
[cited by applicant]
Greene et al., “PPARgamma: Observations in the Hematopoietic System,” Prostaglandins Other Lipid Mediat. 62(1):45-73 (2000).
[cited by applicant]
Hanley et al., “Fetal Epidermal Differentiation and Barrier Development In Vivo is Accelerated by Nuclear Hormone Receptor Activators,” J. Invest. Dermatol. 113(5):788-795 (1999).
[cited by applicant]
Hanley et al., “Glucosylceramide Metabolism is Regulated During Normal and Hormonally Stimulated Epidermal Barrier Development in the Rat,” J. Lipid Res. 38(3):576-584 (1997).
[cited by applicant]
Hanley et al., “Keratinocyte Differentiation is Stimulated by Activators of the Nuclear Hormone Receptor PPARalpha,” J. Invest. Dermatol. 110(4):368-375 (1998).
[cited by applicant]
Hettiarachchi et al., “Western Australian Sandalwood Seed Oil: New Opportunities,” Lipid Technology 2(2):27-29 (2010).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2020/064798 mailed Mar. 22, 2021.
[cited by applicant]
Jung et al., “Peroxisome Proliferator-Activated Receptor γ-Mediated Suppression of Dendritic Cell Function Prevents the Onset of Atopic Dermatitis in NC/Tnd Mice,” J. Allergy Clin. Immunol. 127(2):420-429 (2011).
[cited by applicant]
Kang et al., “Peroxisome Proliferator-Activated Receptors-Gamma Activator, Ciglitazone, Inhibits Human Melanocyte Growth Through Induction of Apoptosis,” Arch. Dermatol. Res. 297(10):472-476 (2006).
[cited by applicant]
Kezic et al., “Filaggrin and Skin Barrier Function,” Curr. Probl. Dermatol. 49:1-7 (2016).
[cited by applicant]
Kim et al., “Limited Cooperation Between Peroxisome Proliferator-Activated Receptors and Retinoid X Receptor Agonists in Sebocyte Growth and Development,” Mol. Genet. Metab. 74(3):362-369 (2001).
[cited by applicant]
Kuwabara et al., “Peroxisome Proliferator-Activated Receptors (PPARs) have Multiple Binding Points that Accommodate Ligands in Various Conformations: Phenylpropanoic Acid-Type PPAR Ligands Bind to PPAR in Different Conf…
[cited by applicant]
Kypriotou et al., “The Human Epidermal Differentiation Complex: Cornified Envelope Precursors, S100 Proteins and the ‘Fused Genes’ Family,” Exp. Dermatol. 21(9):643-649 (2012).
[cited by applicant]
Kömüves et al., “Keratinocyte Differentiation in Hyperproliferative Epidermis: Topical Application of PPARalpha Activators Restores Tissue Homeostasis,” J. Invest. Dermatol. 115(3):361-367 (2000).
[cited by applicant]
Kömüves et al., “Ligands and Activators of Nuclear Hormone Receptors Regulate Epidermal Differentiation During Fetal Rat Skin Development,” J. Invest. Dermatol. 111(3):429-433 (1998).
[cited by applicant]
Lee et al., “PPAR-Gamma Agonist, Ciglitazone, Increases Pigmentation and Migration of Human Melanocytes,” Exp. Dermatol. 16(2):118-123 (2007).
[cited by applicant]
Li et al., “Growth Inhibition and Differentiation Induced by Peroxisome Proliferator Activated Receptor Gamma Ligand Rosiglitazone in Human Melanoma Cell Line A375,” Med. Oncol. 23(3):393-402 (2006).
[cited by applicant]
Li et al., “Comparative Effects of Sandalwood Seed Oil on Fatty Acid Profiles and Inflammatory Factors in Rats,” Lipids 48(2):105-113 (2013).
[cited by applicant]
Michalik et al., “Peroxisome Proliferator-Activated Receptors (PPARs) in Skin Health, Repair and Disease,” Biochim. Biophys. Acta 1771(8):991-998 (2007).
[cited by applicant]
Mittal et al., “Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial,” Ar…
[cited by applicant]
Mizutani et al., “Cooperative Synthesis of Ultra Long-Chain Fatty Acid and Ceramide During Keratinocyte Differentiation,” PLoS One 8(6):e67317 (2013).
[cited by applicant]